The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTPH.L Share News (MTPH)

  • There is currently no data for MTPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Midatech Doses First Patients In MTD201 Administration Method Study

Tue, 08th Oct 2019 11:34

(Alliance News) - Midatech Pharma PLC on Tuesday said a phase one study of MTD201 as a treatment for acromegaly and neuroendocrine tumours has begun.

The goal of the study is to assess subcutaneous administration as an additional injection route versus intramuscular administration.

Acromelagy is hormone disorder which can cause bones in the hands, feet, and face to get bigger. Neuroendocrine tumours affect the cells responsible for releasing hormones.

A previous 2018 study already found that MTD201 had a better long-acting clinical profile when administered as a intramuscular injection compared to Novartis AG's drug Sandostatin. This dosing method study will decide which method of administration will be used in Midatech's pivotal registration study starting 2020.

The first cohort of healthy volunteers in this newer study have been dosed, being 14 of the 28 subjects. The cohort all received one dose of Sandostatin on Friday last week, followed by either a subcutaneous or intramuscular dose of MTD201 on Monday this week.

The other 14 subjects will experience the same procedure later this week, which will complete the study's dosing phase. All subjects will be observed for 63 days before data is analysed. Top line results are due by 2019 end or early 2020.

Shares in Midatech were up 2.2% at 6.26 pence in London late on Tuesday morning.

By Anna Farley; annafarley@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

More News
23 Jun 2021 16:09

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
17 Jun 2021 11:43

AIM WINNERS & LOSERS: Midatech Pharma up 90% on Q-Sphera breakthrough

AIM WINNERS & LOSERS: Midatech Pharma up 90% on Q-Sphera breakthrough

Read more
17 Jun 2021 11:05

Breakthrough with Q-Sphera tech sends Midatech Pharma shares up 80%

Breakthrough with Q-Sphera tech sends Midatech Pharma shares up 80%

Read more
30 Apr 2021 16:32

TRADING UPDATES: Asimilar and Worldsec swing to profit

TRADING UPDATES: Asimilar and Worldsec swing to profit

Read more
25 Mar 2021 17:42

IN BRIEF: Midatech Pharma 2020 loss widens; closes Spanish unit

IN BRIEF: Midatech Pharma 2020 loss widens; closes Spanish unit

Read more
26 Jan 2021 19:25

TRADING UPDATES: Manolete Sets Records; Ergomed Earnings Top Forecasts

TRADING UPDATES: Manolete Sets Records; Ergomed Earnings Top Forecasts

Read more
19 Oct 2020 12:52

Midatech reports 'encouraging' results from MTX110 study

(Sharecast News) - Biotechnology company Midatech Pharma announced "encouraging" headline results from a phase 1 study at the University of California, San Francisco (UCSF) in patients with diffuse intrinsic pontine glioma (DIPG) on Monday.

Read more
19 Oct 2020 10:45

Midatech Pharma Encouraged By Phase One Study Results For MTX110

Midatech Pharma Encouraged By Phase One Study Results For MTX110

Read more
19 Oct 2020 10:26

UK WINNERS & LOSERS SUMMARY: boohoo Down 11% As Weekend Press Weighs

UK WINNERS & LOSERS SUMMARY: boohoo Down 11% As Weekend Press Weighs

Read more
10 Sep 2020 14:57

IN BRIEF: Midatech Pharma Loss Widens In First Half On Lower Revenue

IN BRIEF: Midatech Pharma Loss Widens In First Half On Lower Revenue

Read more
3 Sep 2020 16:00

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
19 Aug 2020 11:35

Midatech Pharma Raises USD1 Million From US Warrants Exercise

Midatech Pharma Raises USD1 Million From US Warrants Exercise

Read more
27 Jul 2020 11:25

Midatech raises £5m to fund Q-Sphera development

(Sharecast News) - Drug delivery technology company Midatech Pharma has raised £5m before expenses via a placing to investors in the UK, it announced on Monday, to advance and develop its 'Q-Sphera' products and technology, and for general corporate purposes.

Read more
27 Jul 2020 10:56

Midatech Pharma Placing And Broker Option Raises Almost GBP6 Million

Midatech Pharma Placing And Broker Option Raises Almost GBP6 Million

Read more
24 Jul 2020 17:24

IN BRIEF: Midatech Pharma Terminates Formal Sales Process

IN BRIEF: Midatech Pharma Terminates Formal Sales Process

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.